Jefferies initiated coverage of Tango Therapeutics with a Buy rating and $19 price target. The company’s two lead assets are both selective PRMT5-MTA inhibitors for MTAP-deletion cancers, which are 10%-15% of all tumors, the analyst tells investors in a research note. The firm says Tango has potentially two differentiated assets.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNGX:
- Tango Therapeutics price target lowered to $13 from $16 at H.C. Wainwright
- Tango Therapeutics price target lowered to $14 from $16 at Guggenheim
- Tango Therapeutics price target lowered to $13 from $18 at Barclays
- Medivir licensee Tango Therapeutics discontinues TNG348 clinical program
- Tango Therapeutics to discontinue development of TNG348 program